Alto Neuroscience
Alto Neuroscience is a clinical-stage biopharmaceutical company that integrates the biology of the patient into drug development to improve the lives of people with mental health conditions.

Co-investors:
Apeiron, What If Ventures, Able Partners, Risk and Return, and Tim Kendall.

Fund III Investment

Andros
Andros (formerly known as CredSimple) is an NCQA-certified SaaS company automating the provider credentialing process for healthcare providers and payors.

Co-investors:
Athena Health, BluePrint Health, Primary Ventures, Bowery Capital, Healthy.vc, and Newark Ventures.

Fund II Investment (Lead)

BluePrint Health
A mentorship-driven startup accelerator program for entrepreneurs involved in the health technology space. Blueprint provides funding, co-working space and guidance to these companies from a sizable network of mentors. Adam Fine is a mentor to BluePrint Health.

Co-investors:
A host of sponsors including insurance companies, hospitals, physicians, healthcare IT companies and startups, pharmacies, and venture capital firms.

Prior and Fund I Investment

Cartiva
Cartiva develops and markets innovative solutions for patients with osteoarthritis, cartilage damage and other musculoskeletal conditions.

Co-investors:
New Enterprise Associates (NEA) and Domain Associates.

Fund I Investment

ChromaCode
ChromaCode’s High-Definition PCR (HDPCRTM) combines proprietary data science with established, low-cost chemistries. They greatly enhance the multiplexing capability of standard qPCR and dPCR machines, thereby lowering cost and democratizing access to molecular diagnostic testing.

Co-investors:
New Enterprise Associates (NEA), Domain Associates, Okapi Ventures and Northpond Partners

Fund III Investment

ClarVista Medical
ClarVista is a medical device company focused on novel solutions in ophthalmology.

Clarvista is developing the HARMONI Modular Intra-Ocular System to optimize vision in the setting of cataract surgery.

Co-investors:
New Enterprise Associates (NEA), and Cycad Group

Fund I Investment

Clever Care
Clever Care is an emerging Medicare Advantage plan that provides culturally sensitive health care solutions and offers its members the best of Eastern and Western medicine

Co-investors:
Health Velocity Capital, Norwest Venture Partners, Global Founders Capital, and Redesign Health

Fund III Investment

ControlRad
ControlRad is a medical technology company focused on reducing radiation exposure to healthcare providers and patients during a wide spectrum of medical procedures.

Co-investors:
Questa Capital

Fund III Investment

Coravin
Coravin markets the Coravin Wine Access System for wine enthusiasts, restaurants, wine stores and wineries. Coravin developed proprietary patented technology to access and pour wine from a bottle without pulling the cork.

Affiliated Investment

Cureatr
Cureatr is a NY-based company helping accountable care organizations, hospitals and health systems, specialty care providers, and physician practice groups improve care coordination through the company's mobile-based platform.

Co-investors:
Deerfield, Cardinal Partners, Cerner Corp, Milestone Venture Partners, JMI

Fund I Investment

CVRx
CVRx is a clinical stage company that has developed proprietary active implantable technology for the treatment of hypertension and heart failure.

Co-investors:
Johnson & Johnson, NEA, Ysios BioFund, Action Potential Venture Capital & Gilde Healthcare Partners

Fund II Investment

Delfi
Delfi Diagnostics, founded by Victor Velculescu at John’s Hopkins, is developing proprietary liquid biopsy-based diagnostic technology for the early detection of cancer.

Co-investors:
Menlo Ventures, illumina Ventures, Samsara Biocapital, and AV8 Ventures

Fund III Investment

Dots
DOTS (Detection on the Spot) is commercializing a novel detection system spanning both industrial and consumer applications.
The first area of focus is a food allergen detection system to test food on the spot to support the millions of consumers with severe food allergies.

Co-investors:
New Enterprise Associates (NEA) and other institutional investors.

Fund II Investment

Earlens
Earlens, a California-based private company, has developed and is marketing a novel hearing solution designed to change the current standard of care for hearing impaired individuals. The Earlens System's unique mechanism of direct sound delivery achieves a level of sound quality unmatched by conventional hearing aids.

Co-investors:
NEA, Lightstone Ventures, Aisling Capital, Vertex Healthcare Ventures, Cochlear and Medtronic.

Fund II Investment

glysens
GlySens has developed and is now testing in clinical trials a novel, long term implant to continuously monitor and transmit blood glucose levels to smart phones and other devices.

Co-investors:
Johnson & Johnson Development Corporation (JJDC) & West Health

Prior Investment

helparound
HelpAround is a mobile virtual safety net for patients with specific conditions and chronic diseases, initially diabetes and food allergies.

Co-investors:
Robert Oringer, Walt Winshall

Fund I Investment

Invuity
Invuity (NASDAQ:IVTY) markets sophisticated optics for illumination and enhanced visualization in surgery.

Invuity completed its IPO in June 2015.

Co-investors:
Kleiner Perkins, Interwest Partners, Valence Advantage (Caxton), Health Care Royalty Partners , Wexford Capital & Wellington Managment

Prior and Fund I Investment

Locemia Solutions
Locemia is developing a novel drug delivery system.

Locemia was acquired by Eli Lilly in October 2015.

Co-investors:
Robert Oringer, Walt Winshall

Fund I Investment

mc10
MC10 is extending human capabilities by making high performance, electronics virtually invisible, conformable and wearable.

Co-investors:
North Bridge, Braemar Energy Ventures, Osage, Aberdare Ventures & Medtronic

Prior and Fund I Investment

Nebula Genomics
Nebula Genomics is a human genome sequencing and health “big data” company on a mission to usher in the mass adoption of gene sequencing by building a large and trusted genomic and healthcare data marketplace for consumers, researchers, and the medical community.

Co-investors:
Khosla Ventures, Arch Venture Partners, Mayfield, Fenbushi Capital, F-Prime Capital Partners and others.

Fund II Investment

Neotract
NeoTract is marketing a novel, office-based, minimally invasive approach for treating benign prostatic hyperplasia. The device provides rapid and long-term relief of obstructive symptoms and does not preclude any other form of therapy, medical or surgical.

Co-investors:
New Enterprise Associates (NEA), Johnson & Johnson Development Corporation (JJDC) & Greenspring Associates.

Fund I Investment

NeuSpera
NeuSpera, based in Santa Clara, CA, is developing injectable neuromodulation devices, so called “electroceuticals,” using licensed mid-field powering technology.

Fund II Investment

Novellus
Novellus, based in Jerusalem, Israel, provides functional information about mutations and their response to drugs, enabling oncologists to treat cancer patients with precision therapies and bio-pharmaceutical companies to develop new drugs more effectively.

Co-investors:
Helsinn, Orbimed, Pontifax, and Bio Capital Impact

Fund II Investment

NovoCure
NovoCure (NASDAQ:NVCR) has developed a novel form of cancer therapy termed Tumor Treatment Fields (TTF) that operates on different principles than standard treatment modalities (surgery, radiation and chemotherapy). The TTF-device has received an initial FDA approval for end stage glioblastoma multiforme and is undergoing several clinical trials for different cancer types.

NovoCure completed its IPO in October 2015.

Co-investors:
WFD Ventures, Index Ventures, Johnson & Johnson Development Corporation (JJDC), Pfizer, Medtronic

Prior Investment

Nuelle (formerly Arisa Health):
Nuelle is a sexual wellness and intimate care company focused on delivering groundbreaking solutions made specifically for women.

Co-investors:
New Enterprise Associates (NEA), Correlation Ventures, and BVCF

Fund I Investment

Nuvaira
Nuvaira is developing a first-in-class bronchoscopic device and procedure to treat lung diseases, including chronic obstructive pulmonary disease (COPD) and asthma.

Co-investors:
Morganthaler Ventures, Advanced Technology Ventures, Split Rock Ventures, Versant Ventures, Vertex Venture Holdings and various undisclosed strategic investors.

Fund I Investment

Personal Genome Diagnostics
Personal Genome Diagnostics (PGDx) is an emerging leader in personalized diagnostics with a proprietary methodology in next generation sequencing (NGS) for use in research and clinical oncology.

Co-investors:
New Enterprise Associates (NEA)

Fund I & Fund II Investment

Revelle Aesthetics
Revelle Aesthetics, the latest ExploraMed Company, is developing a novel medical device in aesthetics.

Co-investors:
NEA and KCK

Fund III Investment

Science Exchange
Science Exchange is an online marketplace for scientific collaboration where researchers can order experiments from the world's best laboratories.

Co-investors:
Union Square Ventures, Index Ventures, Y Combinator and others.

Fund I Investment

SubjectWell
SubjectWell is building the first and only marketplace of patients for clinical trial recruitment.

Co-investors:
Healthy Ventures and Geekdom.

Fund III Investment

tales2go
Tales2Go is a Netflix-Like service that streams thousands of audiobook titles from leading publishers to desktops, laptops and mobile devices in the classroom and beyond.

Affiliated Investment

Upward Health
Upward Health (formerly known as BehaveCare) is an at-risk care coordination company focused on improving outcomes and reducing healthcare costs for certain Medicaid populations.

Co-investors:
Sandbox (Blue Cross Blue Shield Ventures) and Noro-Moseley Partners.

Fund II Investment

Valera Health
Valera Health is a Brooklyn, NY based tele-mental health company which partners with health plans, employers and primary care practices to deliver comprehensive mental health services to patients.

Co-investors:
AXA Venture Partners, The Whittemore Collection, Trinnovate Ventures, StartUp Health, and others.

Fund III Investment

VytronUS
VytronUS is a clinical stage, medical device company developing a novel catheter-based treatment for cardiac arrhythmias with a focus on atrial fibrillation (AFib). 

Co-investors:
New Enterprise Associates (NEA), Apple Tree Partners, BioStar and others.

Fund I Investment

WellDoc
WellDoc has developed an industry-leading, technology-based platform designed to help people with chronic diseases manage their conditions. The company is initially focused on type II diabetes.

Co-investors:
Merck Global Health Initiative

Fund I Investment

Willow
Willow Pump is the first wearable smart breast pump, allowing new mothers to be liberated from wires while discreetly pumping. Willow Pump mobile app allows users to connect on smartphones or tablets via Bluetooth in order to track milk volume in real time, compare data from previous sessions, set alerts, and more.

Co-investors:
New Enterprise Associates (NEA) & Lightstone Ventures

Fund I Investment